嵌合抗原受体
CD30
淋巴瘤
抗原
T细胞
癌症研究
免疫学
生物
免疫系统
作者
Ibrahim N. Muhsen,LaQuisa Hill,Carlos A. Ramos
标识
DOI:10.1016/j.hoc.2023.05.017
摘要
The authors review the current use of chimeric antigen receptor (CAR)-transduced T cells (CAR-T) in Hodgkin lymphoma (HL) and T-cell lymphomas (TCL) and discuss the data on CD30-targeting CAR-T cells, which seem to be safe and effective in HL. In addition, the authors examine the use of CAR-T cells targeting CD30, CD5, or CD7 in TCL, while highlighting the unique challenges of their use in this subset of lymphomas. Furthermore, the authors present future directions and ongoing trials investigating the use of CAR-T cells in TCL and HL.
科研通智能强力驱动
Strongly Powered by AbleSci AI